QDEL.O
Latest Trade
201.24USDChange
-3.25(-1.59%)Volume
1,013,986Today's Range
-
208.1352 Week Range
-
306.72As of on the NASDAQ ∙ Minimum 15 minute delay
Jan 7 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL ANNOUNCES PRELIMINARY REVENUE FOR FOURTH QUARTER 2020; WILL PRESENT VIRTUALLY AT 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.SEES Q4 2020 REVENUE $808 MILLION TO $810 MILLION.INCREASED SCALE MEANINGFULLY OF QUICKVUE AND SOFIA TESTS, EXPECT TO SCALE FURTHER TO OVER 70 MILLION TESTS PER MONTH BY END OF 2021.EXPECT ANOTHER 20,000 SOFIA ANALYZERS WILL BE SHIPPED TO NEW CUSTOMERS IN Q1 ALONE.
Oct 29 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $5.78.Q3 GAAP EARNINGS PER SHARE $5.33.Q3 REVENUE $476.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $450.4 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $4.75 -- REFINITIV IBES DATA.
Oct 1 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL ANNOUNCES PRELIMINARY REVENUE FOR THIRD QUARTER 2020.SEES Q3 2020 REVENUE $475 MILLION TO $477 MILLION.Q3 REVENUE VIEW $394.3 MILLION -- REFINITIV IBES DATA.
Sept 28 (Reuters) - Plexus Corp <PLXS.O>::PLEXUS CORP - ANNOUNCED PARTNERSHIP WITH QUIDEL CORPORATION IN SUPPORT OF SOFIA2 FLUORESCENT IMMUNOASSAY ANALYZER.PLEXUS CORP - CO WILL PROVIDE SUPPLY CHAIN AND MANUFACTURING SOLUTIONS TO QUIDEL.
Sept 1 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL CORP - AUTHORIZED AN INCREASE OF AN ADDITIONAL $150 MILLION TO STOCK REPURCHASE PROGRAM AUTHORIZATION.QUIDEL CORP - BOARD ALSO EXTENDED STOCK REPURCHASE AUTHORIZATION THROUGH AUGUST 28, 2022.
Aug 12 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL’S LYRA® DIRECT SARS-COV-2 ASSAY RECEIVES HEALTH CANADA AUTHORIZATION.QUIDEL CORP - UNDER AUTHORIZATION, LYRA DIRECT SARS-COV-2 ASSAY DOES NOT REQUIRE UPFRONT SAMPLE EXTRACTION.
July 30 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $1.86.Q2 GAAP EARNINGS PER SHARE $1.55.Q2 REVENUE $201.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $189.8 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $1.10 -- REFINITIV IBES DATA.QTRLY TOTAL SALES OF COVID-19 PRODUCTS WERE $109.0 MILLION.
July 6 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL ANNOUNCES PRELIMINARY REVENUE FOR SECOND QUARTER 2020.SEES Q2 2020 REVENUE $201 MILLION TO $202 MILLION.IN JUNE, ALSO SHIPPED ABOUT 1,500 SOFIA INSTRUMENTS.
May 8 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL RECEIVES EMERGENCY AUTHORIZATION FOR RAPID ANTIGEN COVID-19 DIAGNOSTIC ASSAY.SOFIA® 2 SARS ANTIGEN FIA POINT-OF-CARE TEST OFFERS POSITIVE RESULTS IN 15 MINUTES.ASSAY IS CURRENTLY AVAILABLE FOR SALE IN UNITED STATES UNDER EUA, AND QUIDEL IS NOW SHIPPING PRODUCT TO ITS CUSTOMERS.RECEIVED EMERGENCY USE AUTHORIZATION (EUA) FROM U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO MARKET ITS SOFIA® 2 SARS ANTIGEN FIA.
May 6 (Reuters) - Quidel Corp <QDEL.O>::QUIDEL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.22.Q1 GAAP EARNINGS PER SHARE $0.93.Q1 REVENUE $174.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $160.7 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.95 -- REFINITIV IBES DATA.SAYS RECEIVED EMERGENCY USE AUTHORIZATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR LYRA SARS-COV-2 ASSAY.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.